How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin's Rare Disease Portfolio [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Amicus Therapeutics' fair value estimate has been maintained at US$14.50 per share, with analysts keeping the central price target steady despite several small model tweaks. Much of the current debate is linked to the proposed BioMarin acquisition. Supporters see Amicus as a key piece of a larger rare disease portfolio, while critics focus on execution and integration risk. As you read on, you will see how these differing perspectives can inform your own view of the evolving Amicus story. Stay updated as the Fair Value for Amicus Therapeutics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Amicus Therapeutics. What Wall Street Has Been Saying ?? Bullish Takeaways Several firms highlight the proposed Amicus acquisition as an important part of the story for BioMarin, with Oppenheimer explicitly pointing to the expected close of the deal alongside upcoming clinical readouts as a key element in its thesis.
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate UpdatesGlobeNewswire
- TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]Yahoo! Finance
- Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 2/20/26 - Beat
FOLD
Sec Filings
- 3/4/26 - Form 4
- 3/3/26 - Form 8-K
- 3/2/26 - Form 144
- FOLD's page on the SEC website